Moderna Earnings Preview: What to Expect

Company Overview - Moderna, Inc. is valued at $10.7 billion and specializes in mRNA therapeutics and vaccines, notably its COVID-19 vaccine, Spikevax [1] Upcoming Earnings - The company is expected to announce its third-quarter results on November 6, with analysts predicting a loss of $2.03 per share, a significant decline from a profit of $0.03 per share in the same quarter last year [2] Future Projections - For fiscal year 2025, analysts anticipate a loss of $9.67 per share, which is 9% lower than the projected loss of $8.87 per share for 2024 [3] Stock Performance - Over the past 52 weeks, Moderna's stock has decreased by 49.7%, underperforming the S&P 500 Index, which gained 14.5%, and the Health Care Select Sector SPDR Fund, which declined by 3.4% [4] Recent Developments - On October 13, shares of Moderna saw a slight increase following positive early results for its investigational cancer therapy, mRNA-4359, in combination with Merck's Keytruda, showing a 24% objective response rate in melanoma patients [5] Analyst Ratings - The stock has a consensus "Hold" rating, with 24 analysts providing varied opinions: three "Strong Buys," 17 "Holds," one "Moderate Sell," and three "Strong Sells." The mean price target is $42.45, indicating a potential upside of 58.1% from current levels [6]